• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向药物剂量探索研究中纵向有序多重毒性结局建模的比例优势假设:54项研究的汇总分析

Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studies.

作者信息

Drubay Damien, Collette Laurence, Paoletti Xavier

机构信息

INSERM U1018, CESP, Université Paris-Saclay, UVSQ, Villejuif, F-94805, France.

Gustave Roussy, Service de Biostatistique et D'Epidémiologie, Villejuif, F-94805, France.

出版信息

Contemp Clin Trials Commun. 2020 Jan 25;17:100529. doi: 10.1016/j.conctc.2020.100529. eCollection 2020 Mar.

DOI:10.1016/j.conctc.2020.100529
PMID:32055745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7005415/
Abstract

BACKGROUND

Data generated by phase I trials is richer than the classical binary DLT measured at the first cycle used as primary endpoints. Several works developed designs for more informative endpoints, e.g. ordinal toxicity grades and/or longitudinal data which relied however on strong assumptions, in particular the proportional odds (PO) assumption.

METHODS

We evaluated this PO assumption for the dose and cycle on a large database of individual patient data from 54 phase I clinical trials of molecularly targeted agents. The PO model is a specific case of the continuation ratio logit model (CRLM) with null parameters. We compared the PO and CRLM models using the widely applicable information criterion (WAIC). We considered a longitudinal multivariate ordinal toxicity outcome (cutaneous, digestive, hematological, general disorders, and other toxicities).

RESULTS

WAIC suggested that the CRLM model (WAIC = 30911.58) outperformed the PO model (WAIC = 31432.10). Deviance from PO assumption for dose was observed for digestive and general disorder toxicities. There was moderate cycle effect with slight deviance from PO assumption for the other type of toxicity.

CONCLUSIONS

Designs based on PO for dose should be a useful tool for drug with low expected digestive or general disorder toxicity dose-related incidence.

摘要

背景

I期试验产生的数据比用作主要终点的首个周期所测量的经典二元剂量限制性毒性(DLT)更丰富。有几项研究针对更具信息量的终点开发了设计方法,例如序贯毒性等级和/或纵向数据,然而这些方法依赖于很强的假设,尤其是比例优势(PO)假设。

方法

我们在一个来自54项分子靶向药物I期临床试验的个体患者数据大数据库上,评估了剂量和周期方面的这一PO假设。PO模型是具有零参数的连续比例logit模型(CRLM)的一个特殊情况。我们使用广泛适用信息准则(WAIC)比较了PO模型和CRLM模型。我们考虑了一个纵向多变量序贯毒性结局(皮肤毒性、消化系统毒性、血液学毒性、全身紊乱及其他毒性)。

结果

WAIC表明CRLM模型(WAIC = 30911.58)优于PO模型(WAIC = 31432.10)。在消化系统毒性和全身紊乱毒性方面观察到了与剂量的PO假设的偏差。存在中度的周期效应,在其他类型毒性方面与PO假设略有偏差。

结论

对于预期消化系统或全身紊乱毒性与剂量相关发生率较低的药物,基于PO的剂量设计应是一种有用的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8642/7005415/0c3f0190ffc4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8642/7005415/011417f6755c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8642/7005415/d3bd90753565/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8642/7005415/0c3f0190ffc4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8642/7005415/011417f6755c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8642/7005415/d3bd90753565/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8642/7005415/0c3f0190ffc4/gr3.jpg

相似文献

1
Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studies.靶向药物剂量探索研究中纵向有序多重毒性结局建模的比例优势假设:54项研究的汇总分析
Contemp Clin Trials Commun. 2020 Jan 25;17:100529. doi: 10.1016/j.conctc.2020.100529. eCollection 2020 Mar.
2
Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.序贯毒性分级剂量发现临床试验设计:连续评估法的扩展。
Clin Trials. 2012 Jun;9(3):303-13. doi: 10.1177/1740774512443593. Epub 2012 Apr 30.
3
Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.具有有序毒性分级的剂量发现临床试验设计的比例优势模型。
Stat Med. 2011 Jul 30;30(17):2070-80. doi: 10.1002/sim.4069. Epub 2011 Feb 23.
4
Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels.使用连续剂量水平,依据序贯毒性分级指导肿瘤学试验中的剂量探索。
Entropy (Basel). 2024 Aug 14;26(8):687. doi: 10.3390/e26080687.
5
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.存在相关毒性数据时具有时间趋势检测的重复测量剂量探索设计。
Clin Trials. 2017 Dec;14(6):611-620. doi: 10.1177/1740774517723829. Epub 2017 Aug 2.
6
A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.一种在癌症I期试验中使用具有序贯毒性等级的剂量组合的贝叶斯自适应设计。
Stats (Basel). 2020 Sep;3(3):221-238. doi: 10.3390/stats3030017. Epub 2020 Jul 17.
7
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.在肿瘤学 I 期临床试验中,使用混合效应比例优势模型对纵向分级毒性数据进行剂量探索设计。
Stat Med. 2013 Dec 30;32(30):5430-47. doi: 10.1002/sim.5960. Epub 2013 Sep 10.
8
Dose finding with longitudinal data: simpler models, richer outcomes.基于纵向数据的剂量探索:更简单的模型,更丰富的结果。
Stat Med. 2015 Sep 30;34(22):2983-98. doi: 10.1002/sim.6552. Epub 2015 Jun 24.
9
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
10
An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.一种适应性多阶段I期剂量探索设计,纳入了来自多个治疗周期的连续疗效和毒性数据。
J Biopharm Stat. 2019;29(2):271-286. doi: 10.1080/10543406.2018.1535497. Epub 2018 Nov 7.

引用本文的文献

1
Exposure-response modeling for nausea incidence for cotadutide using a Markov modeling approach.采用马尔可夫模型方法对科塔度肽引起恶心发生率的暴露-反应关系进行建模。
CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1582-1594. doi: 10.1002/psp4.13194. Epub 2024 Jul 23.

本文引用的文献

1
Stan: A Probabilistic Programming Language.斯坦:一种概率编程语言。
J Stat Softw. 2017;76. doi: 10.18637/jss.v076.i01. Epub 2017 Jan 11.
2
Bayesian optimal interval design with multiple toxicity constraints.具有多重毒性约束的贝叶斯最优区间设计
Biometrics. 2018 Dec;74(4):1320-1330. doi: 10.1111/biom.12912. Epub 2018 Jun 5.
3
Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.建模细胞毒剂 I 期临床试验中不良事件计数。
Clin Trials. 2018 Aug;15(4):386-397. doi: 10.1177/1740774518772309. Epub 2018 May 19.
4
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.存在相关毒性数据时具有时间趋势检测的重复测量剂量探索设计。
Clin Trials. 2017 Dec;14(6):611-620. doi: 10.1177/1740774517723829. Epub 2017 Aug 2.
5
Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes.剂量探索方法:从 3 + 3 方法走向更丰富的结果。
Clin Cancer Res. 2017 Aug 1;23(15):3977-3979. doi: 10.1158/1078-0432.CCR-17-1306. Epub 2017 Jun 19.
6
Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials.I期癌症试验中采用过量控制方法进行剂量递增的毒性依赖性可行性界限
Stat Med. 2017 Jul 20;36(16):2499-2513. doi: 10.1002/sim.7280. Epub 2017 Mar 15.
7
A decision-theoretic phase I-II design for ordinal outcomes in two cycles.针对两个周期中有序结局的决策理论I-II期设计。
Biostatistics. 2016 Apr;17(2):304-19. doi: 10.1093/biostatistics/kxv045. Epub 2015 Nov 9.
8
Dose finding with longitudinal data: simpler models, richer outcomes.基于纵向数据的剂量探索:更简单的模型,更丰富的结果。
Stat Med. 2015 Sep 30;34(22):2983-98. doi: 10.1002/sim.6552. Epub 2015 Jun 24.
9
Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity.使用马尔可夫模型计算毒性条件概率的适应性I期临床试验设计。
J Biopharm Stat. 2016;26(3):475-98. doi: 10.1080/10543406.2015.1052492. Epub 2015 Jun 22.
10
Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology.迈向使用全谱早期临床试验数据:一项回顾性分析,以比较肿瘤学中分子靶向治疗的潜在纵向分类模型
Stat Med. 2015 Sep 30;34(22):2999-3016. doi: 10.1002/sim.6548. Epub 2015 Jun 8.